"For newborns (0-2 months), RSV hospitalizations dropped significantly in the 2024-2025 RSV season compared to pre-pandemic rates, suggesting vaccine and treatment impacts."
"Excluding the Houston surveillance site data reveals an even greater decline in RSV hospitalizations among infants, indicating potential effectiveness of the new interventions."
A recent CDC study analyzed RSV hospitalization rates comparing the 2024-2025 season to pre-pandemic years. Notably, there was a 52% decrease in hospitalizations for newborns (0-2 months) in RSV-NET, and a 45% decrease in NVSN, with one site in Houston showing a 71% decline when excluded. For infants aged 0-7 months, reductions were 43% and 28% respectively. Conversely, rates for toddlers and children under 5 increased, indicating a potentially more severe RSV season and casting doubt on the overall effectiveness of the new vaccines.
Read at Ars Technica
Unable to calculate read time
Collection
[
|
...
]